{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.5","value":"8.6"},{"groupId":"OG001","spread":"3.3","value":"7.6"}]}],"title":"TOTPAR5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.0","value":"19.7"},{"groupId":"OG001","spread":"6.5","value":"16.7"}]}],"title":"TOTPAR10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.3","value":"32.9"},{"groupId":"OG001","spread":"10.0","value":"27.1"}]}],"title":"TOTPAR15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.4","value":"78.3"},{"groupId":"OG001","spread":"20.8","value":"61.0"}]}],"title":"TOTPAR30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.9","value":"126.3"},{"groupId":"OG001","spread":"32.0","value":"95.5"}]}],"title":"TOTPAR45"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.5","value":"176.4"},{"groupId":"OG001","spread":"43.6","value":"131.2"}]}],"title":"TOTPAR60"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"Pain relief (PAR) was assessed by the participant on a 5-point scale (1=No relief, 2=A little relief, 3=Moderate relief, 4=A lot of relief, 5=Complete relief) at 5, 10, 15, 30, 45 and 60 minutes after each dose of study medication during each breakthrough pain episode. TOTPAR was calculated as the time-weighted sum of the PAR scores at each time point using the following formulas: TOTPAR5=(5\\*PAR5), TOTPAR10=(5\\*PAR5)+(5\\*PAR10), TOTPAR15=(5\\*PAR5)+(5\\*PAR10)+(5\\*PAR15), TOTPAR30=(5\\*PAR5)+(5\\*PAR10)+(5\\*PAR15)+(15\\*PAR30), TOTPAR45=(5\\*PAR5)+(5\\*PAR10)+(5\\*PAR15)+(15\\*PAR30)+(15\\*PAR45), TOTPAR60=(5\\*PAR5)+(5\\*PAR10)+(5\\*PAR15)+(15\\*PAR30) +(15\\*PAR45) +(15\\*PAR60). The minimum and maximum TOTPAR5, TOTPAR10, TOTPAR15, TOTPAR30, TOTPAR45, and TOTPAR60 scores were 5 to 25, 10 to 50, 15 to 75, 30 to 150, 45 to 225, and 60 to 300, respectively. A higher score indicates more pain relief.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received fentanyl sublingual spray 7 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.","id":"OG000","title":"Fentanyl Sublingual Spray"},{"description":"Participants received placebo 3 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Intent-to-treat (ITT) population: All participants in the double-blind treatment period who received at least 1 dose of study medication and had at least 1 pain measurement. 4 of the 96 participants in the ITT population were excluded from analysis because they did not have at least 1 dose of study medication and 1 dose of placebo.","reportingStatus":"POSTED","timeFrame":"5 through 60 minutes after dosing for each pain episode","title":"Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing","type":"SECONDARY","unitOfMeasure":"Units on a scale"}